Bezlotoxumab
Based on 1 publication(s) in Google Scholar
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention.
For research use only. We do not sell to patients.
- Purity: 97.00%
- CAS No.: 1246264-45-8
- Molecular Weight:145.54 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Bezlotoxumab
More
Biological Activity
Human IgG1 kappa
Human
toxin B
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) neutralizes TcdB-induced TER reduction in Caco-2 and MOCK cell monolayers[1].
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) shows increased transport to the apical chamber of Caco-2 cells with rising TcdB concentration[1].
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) inhibits TcdB-induced TER decrease in T84 cell monolayers, with Fc-independent neutralizing effects[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Bezlotoxumab (50 mg/kg, s.c., q.d. for 4 days) enhances survival and reduces symptoms in 100 g male Syrian hamsters with CDI combined with Actoxumab[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week-old female C57BL/6 wild-type or FcRn knockout mice[1]
-
Dosage:250 μg/mouse
-
Administration:i.p., 1 day pre-infection
-
Result:Improved the survival rate of both wild-type and FcRn knockout mice.
Reduced the recurrence of CDI.
-
Animal Model:100 g male Syrian hamsters[1]
-
Dosage:50 mg/kg
-
Administration:s.c., q.d. for 4 days
-
Result:Improved the survival rate.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
4914070 [NCBI]
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1246264-45-8
-
Appearance Liquid
-
Molecular Weight 145.54 kDa
-
Color Colorless to light yellow
-
SMILES
[Bezlotoxumab]
-
Synonyms
BLA761046; MBL-CDB1; MDX-1388
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mucosal Immunol
Clostridioides difficile toxin A and toxin B inhibit toxin-specific adaptive immune responses through glucosyltransferase-dependent activity. [Abstract]2025 Aug 16:S1933-0219(25)00087-X. PMID: 40825509
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Zhang Z, et al. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun. 2015 Jan;83(1):405-16. [Content Brief]
[2]. Navalkele BD, et, al. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics. 2018 Jan 18;12:11-21. [Content Brief]
[3]. Johnson S, et al. Bezlotoxumab. Clin Infect Dis. 2019 Feb 1;68(4):699-704. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz